Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5615666 | The Journal of Heart and Lung Transplantation | 2017 | 8 Pages |
Abstract
End-organ function at implant reliably predicts adverse outcomes and should be considered when making implant decisions. EXCOR use in neonates and infants with CHD should be approached cautiously. If patients have undergone pre-implant CHS and ECMO, EXCOR support may not provide any survival benefit. EXCOR support in non-infants with CHD is challenging but can be consistently successful with appropriate patient selection.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
David L.S. MD, Farhan MD, Christopher S. MD, Charles MD, Francis MD, Jennifer MD, Iki MD, Angela MD,